Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000
Medication labelWhy this: Advisory · dailymed-prescription
Rivastigmine transdermal system is indicated for the treatment of dementia of the Alzheimer’s type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. Rivastigmine transdermal system is indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PDD).
- generic_name
- rivastigmine
- product_names
- rivastigmine
- ndc
- 0378-9070, 0378-9070-16, 0378-9070-93, 0378-9071, 0378-9071-16, 0378-9071-93, 0378-9072, 0378-9072-16, 0378-9072-93
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en